DE69923718D1 - Ppar-alpha und ppar-gamma-hemmer - Google Patents

Ppar-alpha und ppar-gamma-hemmer

Info

Publication number
DE69923718D1
DE69923718D1 DE69923718T DE69923718T DE69923718D1 DE 69923718 D1 DE69923718 D1 DE 69923718D1 DE 69923718 T DE69923718 T DE 69923718T DE 69923718 T DE69923718 T DE 69923718T DE 69923718 D1 DE69923718 D1 DE 69923718D1
Authority
DE
Germany
Prior art keywords
ppar
gamma
alpha
medicinal drug
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69923718T
Other languages
English (en)
Other versions
DE69923718T2 (de
Inventor
Koji Murakami
Tomohiro Ide
Toshiro Mochizuki
Takashi Kadowaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69923718D1 publication Critical patent/DE69923718D1/de
Publication of DE69923718T2 publication Critical patent/DE69923718T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DE69923718T 1999-09-24 1999-09-24 Ppar-alpha und ppar-gamma-hemmer Expired - Lifetime DE69923718T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1999/005217 WO2001021181A1 (fr) 1999-09-24 1999-09-24 INHIBITEURS DE PPARα ET PPAR$g(g)

Publications (2)

Publication Number Publication Date
DE69923718D1 true DE69923718D1 (de) 2005-03-17
DE69923718T2 DE69923718T2 (de) 2006-01-12

Family

ID=14236796

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923718T Expired - Lifetime DE69923718T2 (de) 1999-09-24 1999-09-24 Ppar-alpha und ppar-gamma-hemmer

Country Status (7)

Country Link
US (1) US6762171B1 (de)
EP (1) EP1214939B1 (de)
AT (1) ATE288757T1 (de)
AU (1) AU5759499A (de)
CA (1) CA2383140C (de)
DE (1) DE69923718T2 (de)
WO (1) WO2001021181A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514855A (ja) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
EP1911462A3 (de) 2001-01-26 2011-11-30 Schering Corporation Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
US20030104975A1 (en) * 2001-06-14 2003-06-05 Johan Auwerx Cofactor-based screening method for nuclear receptor modulators and related modulators
CA2576993C (en) * 2004-08-12 2013-09-24 Amgen Inc. Bisaryl-sulfonamides
CA2666670A1 (en) * 2006-10-20 2008-05-02 Dow Global Technologies Inc. Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2014037834A2 (en) * 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0482097B1 (de) * 1989-07-11 2001-06-06 Genentech, Inc. Oberflächenaktive zusammensetzungen und verfahren
EP0788353A1 (de) * 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonisten zur behandlung der fettleibigkeit
AU7493198A (en) * 1997-05-15 1998-12-08 Geoffrey J Schmidt Method of reducing immunological tolerance to malignancy

Also Published As

Publication number Publication date
EP1214939B1 (de) 2005-02-09
CA2383140C (en) 2007-12-04
AU5759499A (en) 2001-04-24
ATE288757T1 (de) 2005-02-15
EP1214939A4 (de) 2003-10-01
DE69923718T2 (de) 2006-01-12
US6762171B1 (en) 2004-07-13
EP1214939A1 (de) 2002-06-19
WO2001021181A1 (fr) 2001-03-29
CA2383140A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
BR0207910A (pt) HidantÈnios e sua utilização no tratamento do diabetes
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
AU8355998A (en) Medicinal compositions with cholesterol-lowering effect
NZ515705A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) alpha
BR0111438A (pt) Análogos de ácido barbitúrico como agentes terapeuticos
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
ZA874812B (en) Drug
BR0012610A (pt) Novo derivado de difenilpiperidina
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
DE69923718D1 (de) Ppar-alpha und ppar-gamma-hemmer
PT1150686E (pt) Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina
EP1284265A4 (de) Benzothiophenderivate und deren medizinische verwendungen
HUP0203884A2 (hu) Kristályos oximinoalkánsav-származékok és cukorbaj elleni alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
FR2387221A1 (fr) Derives du benzimidazole utilisables comme substances actives de medicaments veterinaires
FR2701260B1 (fr) Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2363324A1 (fr) Solutions aqueuses ou hydroalcooliques stables d'essences parfumees ou de medicaments solubles dans l'huile
FR2376661A1 (fr) Medicaments anthelminthiques renfermant comme substances actives des anilinomethylene-malononitriles
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
FR2361110A1 (fr) Medicaments anthelminthiques renfermant une association synergique de substances actives
BRPI0413101A (pt) compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos
FI964303A (fi) Keuhkosydänvian hoitamiseen tarkoitettu aine
HUP0202893A2 (hu) Szubsztituált benziltiazolidin-2,4-dion-származékok és ezeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
8364 No opposition during term of opposition